Early-stage Ovarian Clear Cell Carcinoma (OCCC) Patients at Risk of Recurrence

Not yet recruitingOBSERVATIONAL

Enrollment

272

Participants

Timeline

Start Date

March 15, 2024

Primary Completion Date

October 31, 2024

Study Completion Date

December 31, 2024

Conditions

FIGO Stage IC2 to II Ovarian Clear Cell Carcinoma

All Listed Sponsors

collaborator

Chang Gung Memorial Hospital

OTHER

collaborator

Tokyo University

OTHER

collaborator

Samsung Medical Center

OTHER

lead

National Taiwan University Hospital

OTHER

NCT06237946 - Early-stage Ovarian Clear Cell Carcinoma (OCCC) Patients at Risk of Recurrence | Biotech Hunter | Biotech Hunter